Pharma Company Biokin Considers $432 Million Initial Public Offering in Hong Kong Amid Increased Fundraising Activity
November 7, 2025Biokin, a leading Chinese pharmaceutical company, is currently evaluating a potential initial public offering (IPO) in Hong Kong. The IPO is expected to raise around $432 million amid a surge in fundraising activities within the sector.…
This data comes from the ChinaPulse.com media intelligence and smart news insights monitoring platform.
Original URL: Click here to visit original article